BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Business

  Curadev Announces Research Partnership With University of Texas Southwestern Medical Center, Dallas, TX, USA

  Curadev Pharma, India and UT Southwestern Medical Center in Dallas, USA announce a translational research partnership to identify small molecule drugs for the treatment of specific cancers.

  December 7, 2017

   · 

  1 min read
• Business

  Aerogen Pharma and Lyomark Pharma Partner to Develop Inhaled Surfactant, Begin a Phase II Clinical Trial

  Aerogen Pharma and Lyomark Pharma, an established provider of high-quality medicines for the hospital market, are joining forces to develop a clinically superior treatment for RDS).

  December 7, 2017

   · 

  3 min read
• Business

  Acerus Appoints Mr. Mark Lievonen to Its Board of Directors

  The appointment fills the vacancy resulting from Mr. Tom Rossi’s resignation from the Board of Directors.

  December 7, 2017

   · 

  3 min read
• Drug Development

  Dicerna Announces First Human Dosed in Phase I Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria

  Dicerna is investigating DCR-PHXC for the treatment of primary hyperoxaluria (PH), a group of severe, rare, inherited disorders of the liver that often result in kidney failure.

  December 7, 2017

   · 

  8 min read
• Drug Development

  CEL-SCI Reports Recent Data Review By the Independent Data Monitoring Committee for Its Pivotal Phase III Head and Neck Cancer Study

  CEL-SCI Corporation announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its review of the Phase 3 study data.

  December 7, 2017

   · 

  3 min read
• Business

  Regentys Appoints Dr. Steven D. Wexner Chief Medical Officer

  Dr. Wexner has been a member of the Regentys Medical Advisory Board since January 2014.

  December 7, 2017

   · 

  4 min read
• 

  BioMidwest

  5 Smaller Biotechs That are Flying Under-the-Radar

  These companies are important to follow as they have exponential growth potential and are working on new and innovative drugs.

  December 7, 2017

   · 

  7 min read
• Business

  Aptinyx Bolsters Executive Leadership Team With Appointment of Andy Kidd as CCO

  Andy’s experience will be instrumental in achieving and leveraging anticipated milestones,.

  December 7, 2017

   · 

  3 min read
• Drug Development

  Aptinyx Granted Fast Track Designation, Initiates Phase I for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder

  The U.S. Food and Drug Administration has granted Aptinyx Fast Track designation for the development of NYX-783 for the treatment of PTSD.

  December 7, 2017

   · 

  3 min read
• ZanthoSyn From Cardax Now Available at 3,000+ GNC Corporate Stores in the U.S.

  This nation-wide availability builds on Cardax’s previously announced national purchase order and mutual exclusivity agreement with GNC.

  December 7, 2017

   · 

  4 min read